Oligonucleotides specific for hepatitis B virus

Details Oligonucleotides specific for hepatitis B virus Oligonucleotides specific for hepatitis B virus

2006-01-10

2006-01-10

Wang, Andrew (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S024300, C536S024310, C536S024330

Reexamination Certificate

active

06984729

ABSTRACT:
The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions.

REFERENCES:
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5646262 (1997-07-01), Korba et al.
patent: 5728518 (1998-03-01), Carmichael et al.
patent: WO 92/06693 (1992-04-01), None
patent: 9304701 (1993-03-01), None
patent: 94/24864 (1994-11-01), None
Ono et al., “The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw”, Nucleic Acids Res. 11(6): 1747-1757, 1983.
Uhlmann et al., “Antisense oligonucleotides: A new therapeutic principle”, Chem. Rev. 90(4): 544-584, Jun. 1990.
Oh et al., “Inhibition of hepatitus B virus expression by antisense oligodeoxyribonucleotides”, Korean J. Biochem. 25: 115-120, 1993.
Zhenghong et al., “Comparison of the inhibiting effects of four antisense oligonucleotide phosphorothioates on hepatitus B virus gene expression”, Virologica Sinica 10(1):34-40, Mar. 1995.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93: 3161-3163, Apr. 1996.
Rojanasakul. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug Delivery Rev. 18: 115-131, 1996.
Whitton. Antisense treatment of viral infection. Adv. Virus Res. 44: 267-303, 1994.
Zon et al., “Phosphorothioate oligonucleotides” in Oligonucleotides and Analogues: A Practical Approach, Eckstein ed. IRL Press, New York, pp. 87-108, 1991.
Sureau et al. (1986)Cell47:37-47.
Sells et al. (1987)Proc. Nat. Acad. Sci.84:1005-1009.
Goodarzi et al. (1990)J. Gen. Virol.71:3021-3025.
Blum et al. (1991)Lancet337:1230.
Doong et al. (1991)Proc. Natl. Acad. Sci.(USA) 88:8495-8499.
Korba et al. (1992)Antiviral Res.19:55-70.
Wu et al. (1992)J. Biol. Chem.267:12436-12439.
Jansen et al. (1993)Antimicrob. Agent. Chemother.37:441-447.
Offensperger et al. (1993)EMBO J.12:1257-1262.
Reinis et al. (1993)Folia Biologica(Praha) 39:262-269.
Yao et al. (1994)Nat. Med. J. China74:125.
Gura (1995)Science270:575-577.
Korba et al. (1995)Antiviral Research28:225-242.
Orkin et al. (1995)Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.

Affiliated with

Also associated with

Rating

Oligonucleotides specific for hepatitis B virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligonucleotides specific for hepatitis B virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides specific for hepatitis B virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3532593